Literature DB >> 30940922

Defining orphan conditions in the context of the European orphan regulation: challenges and evolution.

Daniel J O'Connor1, Maria E Sheean2,3, Matthias P Hofer2, Stelios Tsigkos2, Segundo Mariz2, Laura Fregonese2, Kristina Larsson2, Virginie Hivert4, Kerstin Westermark5, Frauke Naumann-Winter6, Violeta Stoyanova-Beninska7, Ingeborg Barišić8, Giuseppe Capovilla9, Armando Magrelli10, Bruno Sepodes11.   

Abstract

Mesh：

Year:  2019        PMID： 30940922     DOI： 10.1038/nrd.2018.128

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  3 in total

Review 1.  [Orphan drugs from the perspective of the Drug Commission of the German Medical Association : Opportunities and challenges].

Authors:  Wolf-Dieter Ludwig
Journal:  Internist (Berl)       Date:  2019-04       Impact factor: 0.743

2.  Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.

Authors:  Kerstin Noëlle Vokinger; Aaron S Kesselheim
Journal:  BMJ Open       Date:  2019-10-10       Impact factor: 2.692

Review 3.  Regulatory Standards in Orphan Medicinal Product Designation in the EU.

Authors:  Stelios Tsigkos; Segundo Mariz; Maria Elzbieta Sheean; Kristina Larsson; Armando Magrelli; Violeta Stoyanova-Beninska
Journal:  Front Med (Lausanne)       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.